Compare HQH & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HQH | PCRX |
|---|---|---|
| Founded | 1986 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | N/A | 2011 |
| Metric | HQH | PCRX |
|---|---|---|
| Price | $19.50 | $20.65 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $35.33 |
| AVG Volume (30 Days) | 183.8K | ★ 1.0M |
| Earning Date | 01-01-0001 | 02-26-2026 |
| Dividend Yield | ★ 11.56% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.09 | 0.47 |
| Revenue | N/A | ★ $716,791,000.00 |
| Revenue This Year | N/A | $6.21 |
| Revenue Next Year | N/A | $8.26 |
| P/E Ratio | ★ $15.24 | $44.07 |
| Revenue Growth | N/A | ★ 3.14 |
| 52 Week Low | $14.31 | $18.80 |
| 52 Week High | $17.94 | $27.64 |
| Indicator | HQH | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 56.88 | 36.78 |
| Support Level | $18.50 | $18.80 |
| Resistance Level | $19.79 | $21.12 |
| Average True Range (ATR) | 0.44 | 1.27 |
| MACD | 0.04 | -0.42 |
| Stochastic Oscillator | 77.22 | 25.00 |
abrdn Healthcare Investors Formerly Tekla Healthcare Investors is the United States based non-diversified closed-end management investment company. Its objective is to seek long-term capital appreciation by investing in securities of healthcare companies. In addition, the fund seeks to provide regular distribution of realized capital gains. The fund invests in the securities of public and private companies.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.